Amgen CEO reports tax-withholding share disposition

Amgen Inc.’s Chairman, CEO and President Robert A. Bradway reported a tax-related share disposition.

(Very High)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Amgen Inc.’s Chairman, CEO and President Robert A. Bradway reported a tax-related share disposition. On March 16, 2026, 21,294 shares of Amgen common stock were withheld at $366.21 per share to cover tax obligations, a non-market transaction classified as a tax-withholding disposition. Following this, Bradway directly holds 501,862 shares of common stock. He also reports indirect holdings of 60,060 shares by a GRAT, 60,060 shares by a spousal GRAT, and 29,940 shares by his spouse. The direct holdings include 2,696 dividend equivalents that will settle in shares as related restricted stock units vest.

Insider Trade Summary

Exercise Price or Tax Liability: 21,294 shares

Exercise Price or Tax Liability 4 txns

Insider Bradway Robert A

Role Chairman, CEO and President

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	21,294	$366.21	$7.80M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 501,862 shares (Direct); Common Stock — 60,060 shares (Indirect, By GRAT); Common Stock — 60,060 shares (Indirect, By Spousal GRAT); Common Stock — 29,940 shares (Indirect, By Spouse)

Footnotes (1)

F1. These shares include 2,696 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Amgen (AMGN) report for Robert A. Bradway?

Amgen reported that Robert A. Bradway had 21,294 common shares withheld to satisfy tax obligations. The Form 4 classifies this as a tax-withholding disposition, not an open-market sale, tied to equity compensation rather than a discretionary trade.

How many Amgen (AMGN) shares does Robert A. Bradway hold after this Form 4?

After the transaction, Robert A. Bradway directly holds 501,862 Amgen common shares. In addition, he reports indirect ownership of 60,060 shares through a GRAT, 60,060 through a spousal GRAT, and 29,940 through his spouse, according to the filing.

Was the Amgen (AMGN) insider transaction an open-market sale?

No, the Form 4 describes the event as a tax-withholding disposition, coded “F.” Shares were delivered to cover tax liabilities at $366.21 per share, rather than being sold in the open market, making it a routine compensation-related transaction.

At what price were Amgen (AMGN) shares withheld for Robert A. Bradway’s taxes?

The filing shows 21,294 Amgen common shares withheld at $366.21 per share. This price is used to value the shares applied against Bradway’s tax obligations arising from his equity compensation, according to the Form 4 disclosure details.

What indirect Amgen (AMGN) holdings does Robert A. Bradway report?

Robert A. Bradway reports indirect ownership of 60,060 Amgen shares held by a GRAT, 60,060 shares held by a spousal GRAT, and 29,940 shares held by his spouse. These positions are listed as indirect holdings separate from his direct share ownership.

What are the dividend equivalents mentioned in the Amgen (AMGN) Form 4 footnote?

The footnote states his direct holdings include 2,696 dividend equivalents credited to unvested restricted stock units. These are paid out in shares of Amgen common stock as the related units vest, with cash paid for any remaining fractional share amounts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 08:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bradway Robert A

(Last)

(First)

(Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS

CALIFORNIA

91320-1799

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman, CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/16/2026		F		21,294	D	$366.21	501,862⁽¹⁾	D
Common Stock								60,060	I	By GRAT
Common Stock								60,060	I	By Spousal GRAT
Common Stock								29,940	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares include 2,696 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Robert A. Bradway	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR